
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Initiates Phase 2 Trial Of Ilofotase Alfa for Kidney Damage
Details : recAP (Ilofotase Alfa), a recombinant alkaline phosphatase, is in Phase 2 trials for cardiac surgery-associated renal damage.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery
Details : Ilofotase Alfa is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, which is investigated for enzyme replacement therapy in adult hypophosphatasia (HPP) patients.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Announces Updated Clinical Development Strategy
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, which is investigated for cardiac surgery-associated renal damage.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Details : Ilofotase Alfa is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypophosphatasia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
July 05, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that was shown in multiple clinical trials to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
March 07, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Kyowa Kirin
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AM-Pharma is entitled to tiered double-digit royalties on sales and a drug supply fee. Kyowa Kirin will gain the exclusive right to develop and commercialize ilofotase alfa in Japan.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : $23.6 million
September 08, 2021
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Kyowa Kirin
Deal Size : $290.0 million
Deal Type : Licensing Agreement
